Multiple Sclerosis Healthy Subjects Clinical Trial
Official title:
A Phase 1, Open-label, 3-treatment Period, 1-sequence, Cross-over Study of the Pharmacokinetics, Safety and Tolerability After Single Ascending Oral Doses of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants.
Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants. Secondary Objective: To assess the tolerability and safety of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants
The duration of the study for a participant will be up to approximately 7 weeks and include: - Screening period: up to 4 weeks (Day -28 to Day -2). - Institutionalization period at each period of treatment: 4 days (Day -1 to Day 3, single SAR443820 administration on Day 1). - Wash-out period: at least 5 days between each dosing. - End-of-study visit: Period 3/ Day 6±1 day. ;